Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback